ReviewFrontiers in endocrinology2018
The Role of Hepatocyte Growth Factor (HGF) in Insulin Resistance and Diabetes.
Review in Frontiers in endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 104 citations in OpenAlex.
- The Lifestyle Modifications and Endometrial Proteome Changes of Women With Polycystic Ovary Syndrome and Obesity.Frontiers in endocrinology · 2022Trial
- Large-Scale Proteomics Uncovers Pre-Disease Inflammation-Lipid Subtypes to Refine Risk Stratification and Prediction of Type 2 Diabetes.Diabetes, obesity & metabolism · 2026Article
- Early-life proteomic and microbiome features signal obesity risk across 26 years of follow-up.mSystems · 2026Article
- Adipocyte-Derived Exosomal miR-5099 Mitigates M1 Macrophage Polarization and Adipose Inflammation via c-Met/NF-κB Axis to Improve Metabolic Health.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- The role of hepatocyte growth factor in the relationship between body fat distribution and plasma markers of glucose metabolism: a cross-sectional study.Diabetology & metabolic syndrome · 2026Article
- Tissue-specific HGF and soluble c-MET levels in gestational diabetes mellitus: insights into maternal-endocrine crosstalk and fetal metabolic adaptation.Endocrine connections · 2026Article
- Modulating Renal Fibrosis: The Emerging Role of Hepatocyte Growth Factor.International journal of nephrology · 2026Review
- DNA methylation-predicted protein differences between Yakutian and Central Russian populations.Epigenomics · 2025Article
- Boosting the engraftment of subcutaneously transplanted pancreatic islets by nanofat.Diabetes, obesity & metabolism · 2025Article
- Article
- Stem cell therapy for diabetes: Advances, prospects, and challenges.World journal of diabetes · 2025Review
- Article
- Plasma Proteomics Reveals Biomarkers and Undulating Changes in Metabolic Aging.Research (Washington, D.C.) · 2025Article
- Recent Research Progress of Wound Healing Biomaterials Containing Platelet-Rich Plasma.International journal of nanomedicine · 2025Review
- KLK8/HGF/Met signaling pathway mediates diabetes-associated hippocampal neuroinflammation in male mice.Theranostics · 2025Article
- WS6 and 5-iodotubercidin small molecules and growth factors; TGF, HGF, and EGF synergistically enhance proliferation of β-like human induced pluripotent stem cells (iPSCs).Journal of diabetes and metabolic disorders · 2024Article
- Metabolic and inflammatory perturbation of diabetes associated gut dysbiosis in people living with and without HIV infection.Genome medicine · 2024Article
- Method to obtain a plasma rich in platelet- and plasma-growth factors based on water evaporation.PloS one · 2024Article
- Novel lipid mediator 7Frontiers in cell and developmental biology · 2024Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In obesity, insulin resistance (IR) and diabetes, there are proteins and hormones that may lead to the discovery of promising biomarkers and treatments for these metabolic disorders. For example, these molecules may impair the insulin signaling pathway or provide protection against IR. Thus, identifying proteins that are upregulated in IR states is relevant to the diagnosis and treatment of the associated disorders. It is becoming clear that hepatocyte growth factor (HGF) is an important component of the pathophysiology of IR, with increased levels in most common IR conditions, including obesity. HGF has a role in the metabolic flux of glucose in different insulin sensitive cell types; plays a key role in β-cell homeostasis; and is capable of modulating the inflammatory response. In this review, we discuss how, and to what extent HGF contributes to IR and diabetes pathophysiology, as well as its role in cancer which is more prevalent in obesity and diabetes. Based on the current literature and knowledge, it is clear that HGF plays a central role in these metabolic disorders. Thus, HGF levels could be employed as a biomarker for disease status/progression, and HGF/c-Met signaling pathway modulators could effectively regulate IR and treat diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.